Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,571 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05783921 | A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 28, 2023 | clinicaltrials |
| NCT05965154 | Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 22 | Second Affiliated Hospital of Guangzhou Medical University |
| 0 |
| Jul 28, 2023 |
| clinicaltrials |
| NCT03925090 | Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03001570 | Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District(FAMOSO) | unknown | Phase 2 | 10 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02760667 | Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer | unknown | Phase 2 | 20 | George Washington UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04619316 | Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition(ERRITI) | unknown | Phase 2 | 70 | University Hospital, EssenOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913414 | Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 120 | Sun Yat-sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04072107 | EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)(EP-STAR) | unknown | Phase 2 | 110 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04221516 | Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 52 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05898256 | Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Guangxi Medical UniversityOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05898373 | Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC | unknown | Phase 1 / Phase 2 | 120 | Peking Union Medical CollegeOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05861557 | Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 23 | Tianjin Medical University General HospitalOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT04586088 | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | unknown | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05229315 | PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma | unknown | Phase 2 | 45 | XIANG YANQUNOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05803915 | Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy | unknown | Phase 2 | 57 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT02285530 | GDF15 Based TPF Induction Chemotherapy for OSCC Patients | unknown | Phase 2 | 72 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05790200 | Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04974866 | Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma | unknown | Phase 2 | 20 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05097209 | Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 200 | Wei JiangOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT01590355 | A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)(ORATOR) | unknown | Phase 2 | 68 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Mar 8, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT04870905 | Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT04929067 | Efficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma: a Phase II Clinical Trial | unknown | Phase 2 | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT05727410 | Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma | unknown | Phase 2 | 50 | Myung-Ju AhnOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05724355 | CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05549466 | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 84 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04405622 | Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | unknown | Phase 2 | 21 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05664906 | Evaluating Chinese Medicine Oral Rinse for Irradiated Oral Mucositis in Head & Neck Cancer Patients | unknown | Phase 1 / Phase 2 | 40 | Chinese University of Hong KongOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT05659186 | PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer | unknown | Phase 2 | 20 | West China HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05611463 | Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients(CHANCE) | unknown | Phase 2 | 25 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05601401 | Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2 | unknown | Phase 2 | 10 | Peking Union Medical College HospitalOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05027204 | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | unknown | Phase 1 / Phase 2 | 94 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 13, 2022 | clinicaltrials |
| NCT00997906 | Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC | unknown | Phase 2 / Phase 3 | 172 | National Cancer Centre, SingaporeOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05551767 | Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer | unknown | Phase 2 | 120 | City Clinical Oncology Hospital No 1OTHER_GOV | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05476965 | Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma(iCSDeR) | unknown | Phase 2 | 20 | Hubei Cancer HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05456022 | Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line | unknown | Phase 2 | 1,000,000 | Cairo UniversityOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT05448885 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT04398056 | Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05351762 | Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC | unknown | Phase 2 | 55 | Xijing HospitalOTHER | 0 | Jul 5, 2022 | clinicaltrials |
| NCT05431764 | Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05420597 | Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma | unknown | Phase 2 | 61 | Fudan UniversityOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05417139 | Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study | unknown | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04978012 | Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy | unknown | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT05350891 | Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC | unknown | Phase 2 | 77 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03854838 | IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jul 28, 2023source: clinicaltrials